Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1982 2
1983 4
1984 4
1985 2
1986 1
1987 1
1991 1
1992 3
1993 2
1994 1
1997 1
1999 3
2000 4
2001 6
2002 2
2003 8
2004 3
2005 2
2006 5
2007 1
2008 2
2009 4
2010 4
2011 4
2012 1
2013 1
2016 3
2019 1
2021 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

74 results
Results by year
Filters applied: . Clear all
Page 1
AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance.
O'Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, Adrian LT, Zhou T, Huang WS, Xu Q, Metcalf CA 3rd, Tyner JW, Loriaux MM, Corbin AS, Wardwell S, Ning Y, Keats JA, Wang Y, Sundaramoorthi R, Thomas M, Zhou D, Snodgrass J, Commodore L, Sawyer TK, Dalgarno DC, Deininger MW, Druker BJ, Clackson T. O'Hare T, et al. Among authors: dalgarno dc. Cancer Cell. 2009 Nov 6;16(5):401-12. doi: 10.1016/j.ccr.2009.09.028. Cancer Cell. 2009. PMID: 19878872 Free PMC article.
The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.
Zhang S, Anjum R, Squillace R, Nadworny S, Zhou T, Keats J, Ning Y, Wardwell SD, Miller D, Song Y, Eichinger L, Moran L, Huang WS, Liu S, Zou D, Wang Y, Mohemmad Q, Jang HG, Ye E, Narasimhan N, Wang F, Miret J, Zhu X, Clackson T, Dalgarno D, Shakespeare WC, Rivera VM. Zhang S, et al. Among authors: dalgarno d. Clin Cancer Res. 2016 Nov 15;22(22):5527-5538. doi: 10.1158/1078-0432.CCR-16-0569. Epub 2016 Oct 25. Clin Cancer Res. 2016. PMID: 27780853 Free article.
SRC inhibitors in metastatic bone disease.
Boyce BF, Xing L, Yao Z, Yamashita T, Shakespeare WC, Wang Y, Metcalf CA 3rd, Sundaramoorthi R, Dalgarno DC, Iuliucci JD, Sawyer TK. Boyce BF, et al. Among authors: dalgarno dc. Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6291s-6295s. doi: 10.1158/1078-0432.CCR-06-0991. Clin Cancer Res. 2006. PMID: 17062716 Free article. Review.
Src inhibitors: genomics to therapeutics.
Sawyer T, Boyce B, Dalgarno D, Iuliucci J. Sawyer T, et al. Among authors: dalgarno d. Expert Opin Investig Drugs. 2001 Jul;10(7):1327-44. doi: 10.1517/13543784.10.7.1327. Expert Opin Investig Drugs. 2001. PMID: 11772255 Review.
Future anti-catabolic therapeutic targets in bone disease.
Boyce BF, Xing L, Yao Z, Shakespeare WC, Wang Y, Metcalf CA 3rd, Sundaramoorthi R, Dalgarno DC, Iuliucci JD, Sawyer TK. Boyce BF, et al. Among authors: dalgarno dc. Ann N Y Acad Sci. 2006 Apr;1068:447-57. doi: 10.1196/annals.1346.042. Ann N Y Acad Sci. 2006. PMID: 16831942 Review.
SRC homology-2 inhibitors: peptidomimetic and nonpeptide.
Sawyer TK, Bohacek RS, Dalgarno DC, Eyermann CJ, Kawahata N, Metcalf CA 3rd, Shakespeare WC, Sundaramoorthi R, Wang Y, Yang MG. Sawyer TK, et al. Among authors: dalgarno dc. Mini Rev Med Chem. 2002 Oct;2(5):475-88. doi: 10.2174/1389557023405765. Mini Rev Med Chem. 2002. PMID: 12370048 Review.
The dynamics and function of calcium-binding proteins.
Levine BA, Dalgarno DC. Levine BA, et al. Among authors: dalgarno dc. Biochim Biophys Acta. 1983 Sep 15;726(3):187-204. doi: 10.1016/0304-4173(83)90005-8. Biochim Biophys Acta. 1983. PMID: 6351918 Review. No abstract available.
74 results